CSK
CSK (C-terminal Src kinase) is a non-receptor tyrosine kinase that restrains Src-family kinases by phosphorylating their C-terminal tails. Through this activity it helps regulate cell growth, differentiation, migration and immune response. Browse Assay Genie's current range of CSK research reagents below, or read on for the biology behind the target.
CSK is a non-receptor tyrosine-protein kinase that phosphorylates tyrosine residues in the C-terminal tails of Src-family kinases (SFKs), including LCK, SRC, HCK, FYN, LYN and YES1. Once the tail is phosphorylated, the SFK engages in an intramolecular interaction between the phosphotyrosine tail and its own SH2 domain, which locks it in an inactive conformation. To inhibit SFKs, CSK is recruited to the plasma membrane by binding to transmembrane or adapter proteins located nearby.
By keeping positive effectors such as FYN and LCK inactive, CSK suppresses signalling from surface receptors including the T-cell receptor (TCR) and B-cell receptor (BCR). It may also act as a negative regulator of EGFR and STAT3 signalling. NCBI describes a role in T-cell activation through its association with the phosphatase encoded by PTPN22, and notes that CSK phosphorylates C-terminal tyrosines on multiple substrates, including SRC.
The CSK gene encodes a protein of the protein kinase superfamily, Tyr protein kinase family, CSK subfamily. HGNC places it in the SH2 domain containing, SH3 domain containing and Csk family tyrosine kinase groups. The protein localises to the cytoplasm and cell membrane, and alternative splicing produces multiple transcript variants. An intronic polymorphism, rs34933034, affects B-cell activation and is associated with systemic lupus erythematosus (SLE). Previously used names include c-src tyrosine kinase and CSK, non-receptor tyrosine kinase.
CSK phosphorylates the C-terminal tails of SRC, LCK, FYN and other SFKs, making it a central model for studying kinase auto-inhibition.
CSK suppresses TCR and BCR signalling by keeping effectors such as FYN and LCK inactive, and it acts with PTPN22 in T-cell activation.
A polymorphism in the CSK gene affects B-cell activation and is associated with systemic lupus erythematosus.
CSK may negatively regulate EGFR and STAT3 signalling, linking it to the control of cell growth, differentiation and migration.
CSK is a non-receptor tyrosine kinase that phosphorylates the C-terminal tails of Src-family kinases such as SRC, LCK and FYN. This drives them into an inactive conformation, so CSK acts as a brake on TCR and BCR signalling and on cell growth, migration and immune response.
HGNC lists the full name as C-terminal Src kinase, and UniProt calls the protein tyrosine-protein kinase CSK. Previous names include c-src tyrosine kinase and CSK, non-receptor tyrosine kinase. No alternative gene symbols are recorded. Alternative splicing gives multiple transcript variants.
An intronic CSK polymorphism, rs34933034, affects B-cell activation and is associated with systemic lupus erythematosus. Orthologues named Csk exist in mouse and rat; check the datasheet of any product for its validated reactivity.
Src-family kinases, the phosphatase PTPN22 and signalling partners that work with CSK in immune receptor and growth factor pathways.
Gene and protein annotations from HGNC, NCBI Gene and UniProt P41240; product specifications from Assay Genie datasheets.